Entropy Technologies LP Acquires Shares of 51,914 DexCom, Inc. (NASDAQ:DXCM)

Entropy Technologies LP bought a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 51,914 shares of the medical device company's stock, valued at approximately $3,480,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. increased its position in shares of DexCom by 0.3% in the first quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company's stock worth $6,186,539,000 after purchasing an additional 136,282 shares during the period. Blair William & Co. IL increased its holdings in DexCom by 1.4% in the 1st quarter. Blair William & Co. IL now owns 4,532,687 shares of the medical device company's stock valued at $628,684,000 after buying an additional 64,683 shares during the period. Legal & General Group Plc lifted its holdings in shares of DexCom by 1.7% during the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company's stock worth $339,352,000 after acquiring an additional 49,076 shares during the period. Massachusetts Financial Services Co. MA boosted its position in shares of DexCom by 16.9% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company's stock worth $276,538,000 after acquiring an additional 353,019 shares in the last quarter. Finally, 1832 Asset Management L.P. boosted its position in shares of DexCom by 1.1% during the 1st quarter. 1832 Asset Management L.P. now owns 1,823,400 shares of the medical device company's stock worth $252,906,000 after acquiring an additional 20,400 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares of the company's stock, valued at $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, EVP Sadie Stern sold 426 shares of the company's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Jacob Steven Leach sold 746 shares of the firm's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by company insiders.

DexCom Price Performance

DexCom stock traded up $4.03 during midday trading on Tuesday, hitting $74.34. 5,467,700 shares of the company's stock were exchanged, compared to its average volume of 3,916,963. The stock has a 50-day moving average price of $69.68 and a two-hundred day moving average price of $92.63. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a market cap of $29.04 billion, a P/E ratio of 42.10, a PEG ratio of 2.15 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

Analysts Set New Price Targets

DXCM has been the topic of a number of research analyst reports. Piper Sandler reaffirmed an "overweight" rating and issued a $90.00 target price on shares of DexCom in a report on Monday, August 26th. JPMorgan Chase & Co. boosted their target price on DexCom from $75.00 to $85.00 and gave the stock a "neutral" rating in a research note on Friday, October 25th. Stifel Nicolaus raised their price target on shares of DexCom from $90.00 to $100.00 and gave the company a "buy" rating in a research note on Friday, August 23rd. Robert W. Baird upped their price objective on shares of DexCom from $80.00 to $82.00 and gave the stock a "neutral" rating in a research report on Monday, August 5th. Finally, StockNews.com downgraded shares of DexCom from a "buy" rating to a "hold" rating in a report on Saturday, November 2nd. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.